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Abstract
Background: The incidence of dengue, an infectious disease caused by dengue virus (DENV), has dramatically
increased around the world in recent decades and is becoming a severe public health threat. However, there is
currently no specific treatment for dengue fever, and licensed vaccine against dengue is not available. Vaccination
with virus-like particles (VLPs) has shown considerable promise for many viral diseases, but the effect of DENV VLPs
to induce specific immune responses has not been adequately investigated.
Results: By optimizing the expression plasmids, recombinant VLPs of four antigenically different DENV serotypes
DENV1-4 were successfully produced in 293T cells. The vaccination effect of dengue VLPs in mice showed that
monovalent VLPs of each serotype stimulated specific IgG responses and potent neutralizing antibodies against
homotypic virus. Tetravalent VLPs efficiently enhanced specific IgG and neutralizing antibodies against all four serotypes
of DENV. Moreover, vaccination with monovalent or tetravalent VLPs resulted in the induction of specific cytotoxic T cell
responses.
Conclusions: Mammalian cell expressed dengue VLPs are capable to induce VLP-specific humoral and cellular
immune responses in mice, and being a promising subunit vaccine candidate for prevention of dengue virus
infection.
Keywords: Dengue virus, VLP, Vaccine
Background
Dengue viruses (DENV) are transmitted among humans
by mosquitos, such as Aedes aegypti and Aedes albopic-
tus [1]. DENV infection may cause a self-limited febrile
illness known as dengue fever (DF), or result in a life-
threatening dengue hemorrhagic fever or dengue shock
syndrome (DHF/DSS). It has been estimated that 50-100
million cases of DF and 250,000-500,000 cases of DHF
occur annually [2], mainly in tropical and subtropical
regions of the world. Dengue viruses, exist as four sero-
types, belong to the family of Flaviviridae,g e n u sFlavi-
virus. The virion contains a positive-sense single-strand
RNA genome with a long open reading frame coding
for capsid (C), premembrane(prM), and envelope(E)
structural proteins, as well as seven non-structural(NS)
proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5[3].
Because of the widespread geographical distribution
and the severe clinical symptoms, dengue vaccine is
urgently needed. However, licensed vaccine is not cur-
rently available for prevention of DENV infection. One
major reason is the phenomenon of antibody depen-
dent-enhancement (ADE), which is known as that a sub-
sequent infection with an alternate serotype can
enhance severity of dengue disease [1]. One explanation
of this phenomenon is that pre-existing non-neutralizing
antibodies may enhance capacity of the new infecting
DENV to access FcgR bearing cells. Therefore, DENV
infection commonly lacks of antibody cross-protection
among serotypes. Various strategies have been used to
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are the live-attenuated tetravalent vaccines of which the
clinical trials are in progress [4-7]. One example is the
Sanofi Pasteur’s dengue vaccine candidate, which is
based on a backbone of yellow fever vaccine (YF 17D)
replication genes and incorporates the envelope genes of
the four dengue virus serotypes, entered its final stage of
clinical development in Australia. However, concerns
have been raised about interference in virus replication
among serotypes [8]. If the replication of four serotypes
of vaccine viruses is not balanced, the replication of
non-dominant serotypes can be interfered by dominant
serotypes, which can result in preferential antibody
response to the dominant strains and lead to a risk of
developing more serious disease [9]. Thus, an ideal den-
gue vaccine should induce neutralizing antibody
responses against all four serotypes simultaneously and
it must be safe to use.
To develop an effective and safe dengue vaccine, we
tested the effect of recombinant dengue virus-like parti-
cles (VLPs). Virus-like particle vaccine has shown con-
siderable promise as vaccine candidate for many viral
diseases [10-13]. VLPs, which are similar to infectious
virions in the structural and physicochemical features,
are non-infectious particles and have advantages in
safety and manufacturing. VLPs can be produced in
multiple expression systems such as E.coli, yeast, baculo-
virus and mammalian cells. Recombinant VLPs can be
efficiently taken up, internalized and processed by anti-
gen presenting cells (APCs) [11], and capable to elicit
strong humoral and cellular immune responses against
viruses [14-16]. Recombinant VLPs of flaviviruses have
been shown to be produced efficiently by co-expressing
the prM and E proteins in the absence of C protein
[17-19].
In this study, four serotypes of dengue virus-like parti-
cles containing recombinant prM and E proteins were
generated in mammalian cells, and their immunogeni-
city was evaluated in BALB/c mice. The results showed
that monovalent VLPs of each serotype could stimulate
specific IgG and neutralizing antibody against homoty-
pic virus, and tetravalent VLPs could induce specific
IgG and neutralizing antibodies against all four sero-
types of dengue virus. Moreover, vaccination with
monovalent or tetravalent VLPs also resulted in the
induction of specific cellular responses. Therefore, den-
gue VLPs can be a potential vaccine candidate for the
prevention of dengue infection.
Materials and methods
Cells and viruses
293T cells (ATCC No.CRL-11268) were cultured in
Dulbecco’s Modified Eagle Medium (DMEM; Gibco)
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), penicillin (100 U/ml) and streptomycin
(100 μg/ml) at 37°C with 5% CO2. C6/36 Aedes albopic-
tus cells (ATCC No.CRL-1660) were grown at 28°C
without CO2 in Eagle’s Minimum Essential Medium
(EMEM; Gibco) supplemented with FBS, penicillin and
streptomycin as well.
Each serotype of dengue virus was passaged and pro-
pagated in C6/36 cells. The DENV-1 strain GZ01/95
and DENV-2 strain ZS01/01 were supplied by the
Department of Microbiology, Zhongshan School of
Medicine, Sun Yat-sen University, China. DENV-1 strain
H a w a i i ,D E N V - 2s t r a i nN G C ,D E N V - 3s t r a i nH 8 7a n d
DENV-4 strain H241 were preserved by our laboratory.
Strain GZ01/95, ZS01/01, H87 and H241 were used for
RNA extraction and then VLPs expression plasmids
construction while strain Hawaii, NGC, H87 and H241
were used for neutralization analysis. Japanese encepha-
litis virus (JEV) strain SA14-14-2 was also propagated in
C6/36 cells and mainly used for cDNA cloning.
Construction of DENV VLP expression plasmids
The QIAamp Viral RNA Kit (Qiagen, Santa Clarita, CA)
was used to extract genomic RNA of DENV1-4 and JEV
from 140 μl C6/36 cells culture supernatant infected
with each virus. The extracted RNA was subjected to
RT using Transcriptor High Fidelity cDNA Synthesis Kit
(Roche, Cat. No. 05081955001) to generate cDNA tem-
plates for amplification of target genes. The PCR seg-
ments were digested with NheI and NotI enzymes and
inserted into NheI and NotI sites of pcDNA5/FRT
vector.
Three types of expression plasmids were constructed
for each serotype of DENV (Figure 1A). The first type
of plasmids was named pD1-D4prME, with entire prM
and E genes of each DENV serotype cloned into the
pcDNA5/FRT vector. The second type of plasmids was
pJD1-D4prME, with entire prM and E genes of each
DENV serotype and an optimized JEV signal sequence
(JESS) [17,20,21] gene from SA14-14-2 strain. To
further compare the impact of E protein transmem-
brane and cytoplasmatic domains, the third type of
plasmids was designed as chimeric constructs pJD1-
D4prMEΔ20%JEV, which contained JESS and full
length of prM, but replaced the 3’ terminal 20% region
of E gene with the corresponding sequence of JEV
(strain SA14-14-2).
Transient transfection of 293T cells with DENV VLP
expression plasmids
293T cells were prepared in wells of 6-well plates one
day earlier and were transfected with pD1-D4prME,
pJD1-D4prME or pJD1-D4prMEΔ20%JEV for each well
using lipofectamin2000 (Invitrogen, Cat no.11668019)
according to instructions supplied by the manufacturer.
Zhang et al. Virology Journal 2011, 8:333
http://www.virologyj.com/content/8/1/333
Page 2 of 9Briefly, for each plasmid transfection, 8 μll i p o f e c t a -
min2000 was diluted in 200 μlO p t i - M E M( G i b c o ) ,a n d
after incubating for 5 min at room temperature the
diluted lipofectamin2000 was combined with diluted
plasmid DNA (4 μg diluted in 200 μl Opti-MEM). After
20 min’s incubation at room temperature, the mixture
was added to each well with 80%-90% confluence of
293T cells. 48 hours post-transfection, cells and super-
natants were harvested for future use.
Western blot analysis
Concentrated culture supernatants were applied to a
NuPAGE 4-12% Bis-Tris gradient gel, and followed by
electroblotting onto PVDF membrane. Non-denatured
proteins were then probed with E protein specific rabbit
polyclonal sera which were produced in our laboratory.
A goat anti-rabbit IgG conjugated to HRP was used as
the secondary antibody. The reactions were detected by
3,3’ diaminobenzidine (DAB) reagent according to the
manufacturer’s instructions.
Purification of DENV VLPs and virions
For DENV1-4 VLPs purification, 293T cells in T175
flasks were transiently transfected with optimized plas-
mids of each serotype. The culture supernatants con-
taining extracellular VLPs were harvested routinely
every 2 days, continuously repeated 3 times. To purify
DENV1-4 virions which were used for electron micro-
scopy and mice immunization, C6/36 cells in T175
flasks were infected with DENV strain Hawaii, NGC,
H87 and H241 respectively. At 7 days after infection,
the supernatants were harvested and inactivated with
1:2000 b-propionolactone.
Cell supernatants collected from dengue VLPs produc-
tion cells or dengue virus infected C6/36 cells were clar-
ified by centrifugation at 10 000× g for 30 min followed
by concentration using ultrafiltration system Vivaflow
200 (Sartorius stedim biotech). The concentrated culture
supernatants were then purified by a two-step ultracen-
trifugation. The first step was a rate zonal centrifuga-
tion. Samples were added on the top of a 15-60%
sucrose gradient and ultracentrifuged in a SW41 rotor
(Beckman Coulter Inc.) at 38,000 rpm at 4 °C for 4 h.
About 1 ml fractions were collected and pelleted by a
second ultracentrifugation and then resuspended in PBS.
The total protein concentrations of authentic virions
and dengue VLPs were determined by Pierce BCA Pro-
tein Assay Kit.
Transmission Electron microscopy (TEM)
Purified dengue VLPs and dengue virions from sucrose
density-gradient fractions were fixed with 2% glutaralde-
hyde. Small droplets of fixed samples were placed on
copper formvar-coated grids for 1 min, then the grids
prM JEV-E20% JESS
E prM
E prM JESS
S''SU0(
pJD1-D4prME
pJD1-D4prMEΔ20%JEV
A
B
EΔ20%
M D 1 D 2D 3 D 4 D 1D 2 D 3D 4 D 1 D 2D 3D 4
pDprME pJDprMEΔ20%JEV pJDprME
~60KD
Figure 1 Construction strategies and secretion analysis of DENV1-4 VLPs. A) Schematic representation of three strategies to construct
DENV1-4 VLP expression plasmids, pD1-D4prME include the entire prM and E gene regions of DENV. JEV signal sequence (JESS) is introduced to
the N-terminal of pJD1-D4prME, and pJD1-D4prMEΔ20%JEV. The corresponding JEV-E sequence was constructed in pJD1-D4prMEΔ20%JEV to
replace the 20% C-terminal region of DENV-E; B) Western blot analysis of DENV1-4 VLPs secretion, Concentrated culture supernatants from 293T
cells transformed with pD1-D4prME, pJD1-D4prME or pJD1-D4prMEΔ20%JEV were tested by rabbit polyclonal serum specific against dengue E
protein. Bound antibodies were detected by a HRP-conjugated goat anti-mouse antibody. The band corresponding to envelope (E) is indicated
with an arrow to the right of the blot.
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(excess samples of each step were removed). At last, the
grids were visualized by TEM.
Mice immunization
Four to six-week-old female BALB/c mice were pur-
chased from Chinese Academy of Medical Sciences
Breeding Laboratories and were intraperitoneally (i.p.)
inoculated with monovalent DENV VLPs (100 μgp e r
dose) or a tetravalent combination (25 μg of each sero-
type per dose) in Freund’s complete adjuvant (Sigma)
for priming and in Freund’s incomplete adjuvant for two
times of boosting at an interval of 2 weeks. Equal
amount of DENV virions (100 μgf o rm o n o v a l e n tv a c -
cine and 25 μg of each serotype for tetravalent vaccine)
were used as controls with the same regimen. On days
0, 14 and 28, blood samples were collected through tail
vein for measurement of serum IgG. At 2 weeks after
the last inoculation, mice were sacrificed to collect
serum for the neutralizing antibodies assay and sepa-
rated splenocytes for testing cytotoxic T cell responses.
ELISA to measure serum IgG
VLPs specific serum IgG antibodies were titred by the
binding capacity with rEIII protein, a recombinant pro-
tein that chimericly expressed DENV1-4 EIII domains in
a certain order and previously produced in our labora-
tory. IgG titers were measured using enzyme-linked
immunosorbent assay (ELISA). Briefly, 200 ng purified
rEIII per well was coated on 96-well plates at 4°C over-
night. Then, the plates were blocked with 5% skimmed
milk in PBS for 1 h, and incubated with 2-fold serial
diluted serum samples (starting from 1:50) at 37°C for 1
h. Bound IgG was detected by HRP-conjugated goat
anti-mouse IgG (Sigma). After addition of 3,3’,3 , 5 ’-tet-
ramethylbenzidine (TMB), absorbance was measured at
450 nm. The value which exceeds the mean+2 S.D. of
negative control was considered positive.
Antibody neutralization assay
The neutralization ability of serum antibodies against
DENV was determined using CPE-determination assays.
Briefly, mice sera from all groups were heat-inactivated
at 56°C for 30 min, then the sera were two-fold serial
diluted from 1:5 to 1:160 in Eagle’s medium supplemen-
ted with 1% heat-inactivated FBS, penicillin and strepto-
mycin and mixed with 100TCID50 virus. After 1 h
incubation at 37°C, 100 μl of virus-serum mixture was
inoculated to the confluent monolayer of BHK-21 cells
in 96-well plates. Every dilution of each serum was per-
formed in quadruplicate. The plates were then incubated
in a CO2 incubator at 37°C for 7 days. The neutraliza-
tion titer was expressed as the maximum serum dilution
at which the CPE of the virus was not observed in all
four wells.
Enzyme Linked Immunospot (ELISPOT) Assay
The ELISPOT 96-well plates (BD) were coated with 100
μl of anti-mouse IFN-g (5 μg/ml in coating buffer) at 4°
C overnight. The following day, plates were washed and
blocked with blocking solution for 2 h. Then, 100 μl
freshly isolated splenocytes (5 × 10
5 cells) from the
immunized mice were added to each well and stimu-
lated with DENV VLPs at 37°C for 40 h. After cells
were washed out, biotinylated anti-mouse IFN-g was
added to each well and incubated for 2 h at room tem-
perature. Thereafter, the plates were washed and incu-
bated for 1 h at room temperature with streptavidin-
HRP. Finally, AEC substrate solution (BD) was added
and spots were counted by ImmunoSpot
® Analyzer
(Cellular Technology Ltd.).
Statistical analysis
Statistical comparisons among groups were analyzed by
one way ANOVA using SPSS 11.5. A P value less than
0.05 was considered statistically significant.
Results
Production of DENV VLPs
To optimize the production of DENV VLPs, three types
of expression plasmids encoding prM and E glycopro-
teins were constructed for each serotype (Figure 1A). E
and prM proteins were chosen as two subunits of
recombinant VLPs, because the former one constitutes
the spikes on DENV membrane surface and is known as
the major protective antigen of DENV to induce neutra-
lizing antibodies, and the latter one is also embedded in
the viral envelop and contributes to the stability of E
protein. To test the secretion of DENV VLPs from tran-
sient transfected 293T cells, culture supernatants of
293T cells were collected and identified by western blot
analysis for E protein expression (Figure 1B). Cells
transfected with pD1-D4prME plasmids that express full
length of prM and E proteins could express intracellular
proteins (data not shown). However, due to the lack of
signal sequence, they could not secret VLPs into tissue
culture. When adding a JEV signal sequence at the N-
terminal of full length of prM and E genes, cells trans-
fected with expression plasmid pJD1prME could effec-
tively secret VLPs, but cells transfected with pJD2-
D4prME still could not secret VLPs. When both carry-
ing a N-terminal JEV signal sequence and replacing C-
terminal 20% regions of DENV E gene with the corre-
sponding region of JEV E gene, all four constructs,
pJD1-D4prMEΔ20%JEV, could secrete VLPs into tissue
culture. Therefore, we chose pJD1prME and pJD2-
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Page 4 of 9D4prMEΔ20%JEV to express recombinant DENV1 and
DENV2-4 VLPs in 293T cells, respectively.
To compare the size and morphology of recombinant
DENV1-4 VLPs and their corresponding serotype of
DENV virions, purified dengue VLPs and virions were
observed under transmission electron microscopy
(TEM) (Figure 2). All four types of recombinant VLPs
exhibited as electron-dense spherical particles of 45-55
nm size, which were similar to the morphology and size
of DENV virions. Therefore, by optimizing the express
plasmids and using mammalian 293T cells, we success-
fully acquired DENV VLPs which consisted of major
antigenic proteins of the virus and exhibited similar
morphological features as nature virus particles.
DENV VLPs elicited virus specific IgG and neutralizing
antibodies
To evaluate humoral responses induced by recombinant
VLPs, BALB/c mice were immunized with monovalent
dengue VLPs of each serotype or their corresponding
virion counterparts for three times at two-week inter-
vals. Serum samples were collected after 2 weeks of
each immunization, and analyzed for IgG antibodies
specific against rEIII, a recombinant protein that
expressed chimerical EIII domains of all four DENV
serotypes. EIII domain of DENV contains several neu-
tralizing epitopes and host cell receptor recognition
sites. As shown in Figure 3A-D, in comparison to the
PBS control, mice immunized with either dengue VLPs
or virions induced high level of rEIII specific serum IgG.
For DENV-1, DENV-2 and DENV-4 VLPs, they induced
even higher IgG responses than DENV-1, DENV-2 and
DENV-4 virions, respectively. Neutralization assays
using serum collected on day 42 demonstrated that
DENV1-4 VLPs could elicit comparable level of homoty-
pic neutralizing antibodies as monovalent dengue virions
(Figure 4A).
The results that monovalent dengue VLPs could effi-
ciently enhance specific IgG and develop neutralization
antibodies, suggested that the tetravalent formulation of
DENV VLPs, which was constituting of four types of
DENV VLPs at equal amount, might be capable to stimu-
late neutralizing antibodies against all four serotypes of
DENV. As generating balanced neutralizing antibodies to
each serotype of a tetravalent dengue vaccine is desired for
its safety and efficacy, a tetravalent dengue VLPs combina-
tion was applied to BALB/c mice for all priming and
boosting immunizations as the regimen used for monova-
lent VLPs vaccination. Tetravalent dengue virions and PBS
were again used as controls. The serum samples collected
A CE
F D B 100nm
100nm
100nm
100nm 100nm
Figure 2 Morphology and size of dengue VLPs and virions. Purified dengue virions (arrow indicated in A) and VLPs (arrow indicated in C-F)
were negatively stained and analyzed by TEM. Scale bar indicates 100 nm. A. Dengue virions, B. Negative control, C. DENV-1 VLPs, D. DENV-2
VLPs, E. DENV-3 VLPs, F. DENV-4 VLPs.
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Figure 3 Virus specific IgG were enhanced by DENV VLPs or virions. BALB/c mice were intraperitoneally immunized with 100 μg
monovalent DENV VLPs or virions (A-D), or tetravalent VLPs or virions (E 25 μg of each serotype) for three times at two-week intervals. At day
14, 28, 42, sera were collected and ELISA was used to test for rEIII specific IgG. Data were expressed as mean titer with a standard deviation (SD)
bar. *indicates statistical significance (P < 0.05).
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Page 6 of 9at Day 14, 28, and 42 post the initial tetravalent VLPs vac-
cination, were analyzed for rEIII specific IgG antibodies.
The data showed that tetravalent virions could stimulate
IgG antibodies against rEIII protein. Intriguingly, tetrava-
lent VLPs could even achieved to a higher level than tetra-
valent virions could induce (Figure 3E). Moreover,
neutralizing antibodies stimulated by tetravalent VLPs
exhibited simultaneous blocking of DENV1-4 infections,
and the blocking effect was comparable to tetravalent for-
mula of virions (Figure 4B).
Therefore, similar as DENV virions, both monovalent
and tetravalent formula of DENV VLPs could effectively
induce virus specific IgG and produce high titer of pro-
tective neutralizing antibodies in vaccinated mice.
DENV VLPs induced virus-specific T cell responses
Lastly, to investigate cellular immune responses trig-
gered by dengue VLPs, ELISPOT assay was employed to
test dengue specific cytotoxic T cell responses. At day
42 after the initial immunization, mice were sacrificed
and spleen cells were collected. Each of the monovalent
DENV1-4 VLPs immunized spleen cells were then in
vitro stimulated with corresponding DENV1-4 VLPs and
monitored for IFN-g production. As depicted in Figure
5A, splenocytes from mice immunized with dengue
monovalent VLPs exibited specific cytotoxic T cell
responses, and the extent was similar to the effect of
monovalent DENV virions. Furthermore, dengue tetra-
valent VLPs manifested high level of IFN-g to in vitro
stimulation with each serotype of DENV1-4 VLPs, and
with no significant differences to the homotypic virions
(Figure 5B). These results demonstrated that vaccination
with either monovalent or tetravalent dengue VLPs
could elicit dengue specific cellular immune responses.
Discussion
Despite many years of efforts, an effective dengue vaccine
has not been developed. Various strategies have been
applied to develop dengue vaccine, such as attenuated
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Figure 4 Serum neutralizing antibody titer of vaccinated mice.
BalB/C mice were immunized with A) 100 μg monovalent VLPs or
virions, B) tetravalent VLPs or virions (25 μg of each serotype) for
three times at two weeks interval. At day 42, the serum neutralizing
antibodies were assessed using CPE-determination assays. Data of
each group was expressed as geometric mean titer (GMT) with an
S.D. bar (n = 5). *indicates statistical significance (P < 0.05). 
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Figure 5 Dengue specific T cell responses evaluated by
ELISPOT assay. BALB/c mice were immunized with DENV1-4 VLPs
or virions in either monovalent A) or tetravalent B) formula. The
immunized mice were sacrificed at day 42 and the collected spleen
cells were isolated and stimulated in vitro with each of DENV1-4
VLPs. ELISPOT assay was performed to test IFN-g production. The
mean number of spot forming cells (SFCs)/10
6 splenocytes was
shown as VLPs-stimulated plus mock-stimulated with an S.D bar.
*indicates statistical significance (P < 0.05).
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Page 7 of 9[22,23], subunit [24,25], chimeric [26,27], and DNA [1,28]
vaccines. Previous studies have shown that co-expressed
prM and E proteins of dengue virus could produce VLPs
in mammalian cells, but the VLPs expression plasmids
were often used as DNA vaccine [17,20,29]. Here we stu-
died on recombinant dengue VLP vaccine as a new candi-
date. VLPs are similar to infectious virions in both
structural and biochemical properties but are non-replicat-
ing and free of genome. Therefore, due to their preserved
immunogenicity in native forms and better safety, VLPs
have been used in many vaccine researches for prevention
of viral diseases [11].
In order to optimize the production of dengue VLPs,
three types of expression plasmids were constructed.
The indirect fluorescent antibody (IFA) assay showed all
constructs could express intracellular VLPs (data not
shown). However, the western blot analysis of culturing
supernatant showed that, pD1-D4prME constructs with-
out signal peptide could not secret dengue VLPs. And
except for pJD1prME, the constructs simply adding a
JEV signal sequence could not secret dengue VLPs. All
constructs which replaced the carboxy-terminal 20% of
DENV E protein with corresponding JEV E protein
could secret VLPs into cell culturing supernatant. Based
on data from these express plasmids, pJD1prME and
pJD2-D4prMEΔ20%JEV were identified as optimized
VLP formation constructs for each DENV serotype.
These data from different express plasmids indicated
that i) signal peptide was one of the most important fac-
tors that influence downstream protein translocation
and topology, thus dictating correct processing of den-
gue virus prM and E proteins by the host encoded sig-
nalase and endopeptidase [20]. ii) the transmembrane
domain of dengue E protein contains a strong ER reten-
tion signal [30,31], replacement of the carboxy-terminal
20% of DENV E protein with the corresponding region
of JEV provides extracellular secretion of DENV2-4
VLPs, but does not produce additional benefit to pro-
mote extracellular secretion of DENV-1 VLPs.
This was different from previous studies [29,32],
which showed that 20% JEV sequence replacement was
absolutely necessary for DENV-1 and DENV-2 VLPs
secretion; DENV-3 plasmids containing either the full-
length DENV-3 E protein gene or the 20% JEV sequence
replacement secreted VLPs to similar levels; Whereas
DENV-4 VLPs were secreted to high levels by plasmids
containing the full-length DENV-4 E protein gene but
not by the chimeric plasmid containing 20% JEV E
replacement. Considering that dengue viruses of differ-
ent serotypes or even among different strains of the
same type, their biological characteristics were not the
same, thus it is essential to use different strategies when
constructed dengue VLPs expression plasmids. As den-
gue particle assembly and secretion is influenced by
interaction of prM and E [29], we inferred that the chi-
meric E (80%DENV and 20%JEV) of DENV2-4 could
interact with DENV2-4 prM, which help to stabilize the
interaction between prM and E and lead to efficient
secretion of VLPs. As for DENV-1 (strain GZ01/95), its
prM and E domains might interact stably enough, and
the replacement of 20% C-terminal region of E would
not improve more on this interaction, therefore DENV-
1 VLPs showed similar secret pattern between
pJD1prME and pJD1prMEΔ20%JEV plasmids.
The immunogenicity of dengue VLPs was evaluated
using BALB/c mice. The analysis of humoral immune
responses revealed that dengue VLPs, in either monova-
lent or tetravalent formula, induced high levels of rEIII-
specific IgG. Because dengue virus-induced neutralizing
antibodies can bind to virus and prevent virus from
binding to host cell receptors, therefore inducing neu-
tralizing antibodies is particularly important to block
virus entry into target cells [33]. In this study, either the
m o n o v a l e n to rt h et e t r a v a l e n tf o r m u l ao fd e n g u eV L P s
could efficiently trigger in vivo development of neutra-
lizing antibodies. Furthermore, the tetravalent formula
of VLPs was able to simultaneously induce balanced
neutralizing antibodies against all four serotypes. All
these results confirmed that all four serotypes of DENV
VLPs prepared in this study preserved the antigenicity
of prM and E proteins.
One of the marked advantages of VLPs is their ability
to induce cellular immunity [34,35]. Since IFN-g consti-
tutes a major mediator of the Th1 cell-mediated
immune response and has been shown to play a key
role in antiviral activity against dengue [36], in our
study, cellular immune responses were assessed by IFN-
g releasing ability of VLPs-stimulated spleen cells.
Spleen cells from mice vaccinated with dengue VLPs
and virions produced comparable levels of IFN-g after in
vitro stimulation with dengue VLPs.
In conclusion, by optimizing the expression plasmids,
we successfully generated recombinant DENV1-4 VLPs in
mammalian cells. Furthermore, the vaccination effect of
VLPs in mice showed that either monovalent or tetrava-
lent formula of dengue VLPs could efficiently elicit virus
specific humoral and cellular immune responses. These
results supplied evidence that VLP vaccine may serve as a
promising strategy for dengue vaccine development.
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